All In Biotech

Drug Trial Radar · NCT05753501

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

135

Actual

Start

Jun 9, 2023

Primary completion

Mar 2031

Study completion Mar 2031

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for the treatment of NHL. This study is a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101. Approximately 200 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide. Participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

Conditions

  • Hematologic Cancer

Interventions

  • ABBV-101Drug

    Oral:Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)Time frame: Up to Approximately 88 Months
  2. Change in Laboratory ParametersTime frame: Up to Approximately 88 Months
  3. Change in Vital SignsTime frame: Up to Approximately 88 Months
  4. Change in Electrocardiogram (ECG)Time frame: Up to Approximately 88 Months

Locations

51 sites in 9 countries. Site status is shown where the registry gives one.

  • Arizona Oncology - Tucson - Wilmot Road /ID# 252351

    Tucson, Arizona

  • UC Irvine Medical Center /ID# 263020

    Orange, California

  • Stanford University - Palo Alto /ID# 249683

    Palo Alto, California

  • Rocky Mountain Cancer Centers - Aurora /ID# 252237

    Aurora, Colorado

  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347

    Chicago, Illinois

  • Beth Israel Deaconess Medical Center /ID# 249302

    Boston, Massachusetts

  • Rutgers Cancer Institute of New Jersey /ID# 249323

    New Brunswick, New Jersey

  • New York Oncology Hematology - Albany Cancer Center /ID# 252240

    Albany, New York

  • Northwell Health - Monter Cancer Center /ID# 250422

    Lake Success, New York

  • University of Rochester Medical Center /ID# 249324

    Rochester, New York

  • University of Cincinnati /ID# 249299

    Cincinnati, Ohio

  • Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309

    Eugene, Oregon

  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center /ID# 249293

    Houston, Texas

  • University Health Network_Princess Margaret Cancer Centre /ID# 253483

    Toronto, Ontario, Canada

  • Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428

    Montreal, Quebec, Canada

  • Hopital Saint-Louis /ID# 253663

    Paris, France

  • Institut Bergonie /ID# 253664

    Bordeaux, Gironde, France

  • CHU Montpellier - Hopital Saint Eloi /ID# 253666

    Montpellier, Herault, France

  • CHRU Lille - Hopital Claude Huriez /ID# 253665

    Lille, Nord, France

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 256248

    Nantes, Pays de la Loire Region, France

  • Institut Gustave Roussy /ID# 253662

    Villejuif, Val-de-Marne, France

  • Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 257431

    Berlin, Germany

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 264566

    Hamburg, Germany

  • Universitaetsklinikum Ulm /ID# 253742

    Ulm, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Wuerzburg /ID# 254636

    Würzburg, Bavaria, Germany

  • Universitaetsmedizin Rostock /ID# 259657

    Rostock, Mecklenburg-Vorpommern, Germany

  • Universitaetsklinikum des Saarlandes /ID# 257435

    Homburg, Saarland, Germany

  • Yitzhak Shamir Medical Center /ID# 254566

    Tsrifin, Central District, Israel

  • Hadassah Medical Center-Hebrew University /ID# 251123

    Jerusalem, Jerusalem, Israel

  • The Chaim Sheba Medical Center /ID# 251122

    Ramat Gan, Tel Aviv, Israel

  • Tel Aviv Sourasky Medical Center /ID# 259608

    Tel Aviv, Tel Aviv, Israel

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII /ID# 260317

    Bergamo, Italy

  • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255172

    Bologna, Italy

  • IRCCS Ospedale San Raffaele /ID# 253531

    Milan, Milano, Italy

  • ASST Grande Ospedale Metropolitano Niguarda /ID# 253532

    Milan, Milano, Italy

  • A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 253530

    Turin, Piedmont, Italy

  • National Cancer Center Hospital East /ID# 250684

    Kashiwa-shi, Chiba, Japan

  • Kyoto University Hospital /ID# 261837

    Kyoto, Kyoto, Japan

  • National Cancer Center Hospital /ID# 250680

    Chuo-ku, Tokyo, Japan

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.